- Home
- Patients and carers
- Clinical Trials
- Looking for a clinical trial
- Solid cancer clinical trials
- Lung cancer clinical trials
If you would like to be considered for a clinical trial you will require a referral from your current treating team.
Visit the Joining a Clinical Trial page for referral information.
For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.
Clinical Trials Enquiry Coordinator
Business hours, Mon to Friday between 9am - 2pm
- Email: Clinical Trials Enquiries
- Phone: (03) 8559 7456
Open and Recruiting Clinical Trials
Trident-1
Title
A phase 1/2, open-label, multi-center, first-in-human study of the safety, tolerability, pharmacokinetics, and anti-tumor activity of TPX-0005 in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 R earrangements
Trial ID
Cancer type
Lung cancer with certain changes in the genes of the cancer (ROS1, NTRK1, NTRK2, or NTRK3)
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
WU-KONG-1
Title
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation
Trial ID
Cancer type
Non-small cell lung cancer with EGFR or HER2 changes in the genes of the cancer
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
Dream3R
Title
DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial
Trial ID
Cancer type
Mesothelioma
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
CIAG933A12101
Title
An open-label, multi-center, phase I study of oral IAG933 in adult patients with advanced mesothelioma and other solid tumors
Trial ID
Cancer type
Mesothelioma
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
FLAGSHP-1
Title
An open-label, multi-center phase 1/1b dose escalation and expansion study of ERAS-601 SHP2 inhibitor as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumors
Trial ID
Cancer type
Non-small cell lung cancer
Status
Open and recruiting
Phase
Phase one: A phase one clinical trial tests new treatments sometimes for the first time in humans, usually in a small group of patients. The aim of a phase one clinical trial is to test the safety of the new treatment and find the best dose to give patients.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
Artemide-01
Title
A phase I/II, open-label, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD2936 anti-TIGIT / anti-PD-1 bispecific antibody in participants with advanced or metastatic non-small cell lung cancer
Trial ID
Cancer type
Non-small cell lung cancer
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
ARROS-1
Title
A phase 1/2 study of the highly selective ROS1 inhibitor NVL-520 in patients with advanced NSCLC and other solid tumors
Trial ID
Cancer type
Non-small cell lung cancer
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
BO42777
Title
A phase I-III, multicenter study evaluating the efficacy and safety of multiple therapies in cohorts of patients selected according to biomarker status, with locally advanced, unresectable, stage III non-small cell lung cancer
Trial ID
Cancer type
Non-small cell lung cancer
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
Skyscraper 5
Title
A phase II, open-label, multicenter study evaluating the safety and efficacy of neoadjuvant and adjuvant Tiragolumab plus Atezolizumab, with or without platinum-based chemotherapy, in patients with previously untreated locally advanced resectable stage II, IIIA, or select IIIB non-small cell lung cancer
Trial ID
Cancer type
Non-small cell lung cancer
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
Pacific-9
Title
A phase III, double-blind, placebo-controlled, randomised, multicentre, international study of Durvalumab plus Oleclumab and Durvalumab plus Monalizumab in patients with locally advanced (stage III), unresectable non-small cell lung cancer (NSCLC) who have not progressed following definitive, platinum-based concurrent chemoradiation therapy
Trial ID
Cancer type
Non-small cell lung cancer
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
PALOMA-3
Title
A phase 3, open-label, randomized study of Lazertinib with subcutaneous Amivantamab administered via manual injection compared with intravenous Amivantamab or Amivantamab subcutaneous on body delivery system in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer after progression on Osimertinib and chemotherapy
Trial ID
Cancer type
Non-small cell lung cancer with EGFR mutation
Status
Open and recruiting
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
ALKOVE-1
Title
A phase 1/2 study of the selective anaplastic lymphoma kinase (ALK) inhibitor NVL-655 in patients with advanced NSCLC and other solid tumours
Trial ID
Cancer type
Non-small cell lung cancer with ALK-positive (ALK+) muation
Status
Open and recruiting
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
SHERLOCK
Title
Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancerwith KRAS G12C mutation
Trial ID
Cancer type
Non-small cell lung cancer with KRAS G12C mutation
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.